Neprilysin inhibition--a novel therapy for heart failure.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Study on the Effects of Angiotensin Receptor/Neprilysin Inhibitors on Renal Haemodynamics in Healthy Dogs.International journal of molecular sciences · 2024
   Article
2. Effects of sacubitril/valsartan on life quality in chronic heart failure: A systematic review and meta-analysis of randomized controlled trials.Frontiers in cardiovascular medicine · 2022
   Review
3. Identification and bioinformatic analysis of neprilysin and neprilysin-like metalloendopeptidases inmicroPublication biology · 2021
   Article
4. Advance for Cardiovascular Health in China.Journal of cardiovascular translational research · 2019
   Review
5. Systematic synthesis of a 6-component organic-salt alloy of naftopidil, and pentanary, quaternary and ternary multicomponent crystals.IUCrJ · 2018
   Article
6. Prevention of Heart Failure in Patients with Diabetes: Role of Diabetes Medications.Current cardiology reports · 2018
   Review
7. Urinary neprilysin in the critically ill patient.BMC nephrology · 2017
   Article
8. Neprilysin Inhibitors in Cardiovascular Disease.Current cardiology reports · 2017
   Review
9. eLife · 2016
   Article
10. Precision medicine in cardiology.Nature reviews. Cardiology · 2016
    Review
11. Neprilysin Inhibition as a PARADIGM Shift in Heart Failure Therapy.Current heart failure reports · 2016
    Review
12. A New Mechanism of Action in Heart Failure: Angiotensin-Receptor Neprilysin Inhibition.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2016
    Review
13. Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.Drug design, development and therapy · 2016
    Review
14. Paradigm-HF: a Paradigm Shift in Heart Failure Treatment?Arquivos brasileiros de cardiologia · 2016
    Article
15. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.Clinical science (London, England : 1979) · 2016
    Review
16. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.Clinica chimica acta; international journal of clinical chemistry · 2015
    Review
17. Emerging Novel Therapies for Heart Failure.Clinical Medicine Insights. Cardiology · 2015
    Review
18. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.Vascular health and risk management · 2015
    Review
19. European society of cardiology and transcatheter cardiovascular therapeutics.P & T : a peer-reviewed journal for formulary management · 2014
    Article

Corrections and comments

• Comment on
  Angiotensin-neprilysin inhibition versus enalapril in heart failure.2014

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as